Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children | Critical Care Medicine | JAMA Pediatrics | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.238.77. Please contact the publisher to request reinstatement.
1.
McDonough  AK, Curtis  JR, Saag  KG.  The epidemiology of glucocorticoid-associated adverse events.   Curr Opin Rheumatol. 2008;20(2):131-137. doi:10.1097/BOR.0b013e3282f51031 PubMedGoogle ScholarCrossref
2.
Fuhlbrigge  AL, Lemanske  RF  Jr, Rasouliyan  L, Sorkness  CA, Fish  JE.  Practice patterns for oral corticosteroid burst therapy in the outpatient management of acute asthma exacerbations.   Allergy Asthma Proc. 2012;33(1):82-89. doi:10.2500/aap.2012.33.3499 PubMedGoogle ScholarCrossref
3.
Freyberg  RH, Traeger  CH, Patterson  M, Squires  W, Adams  CH.  Problems of prolonged cortisone treatment for rheumatoid arthritis; further investigations.   J Am Med Assoc. 1951;147(16):1538-1543. doi:10.1001/jama.1951.03670330030008 PubMedGoogle ScholarCrossref
4.
Volmer  T, Effenberger  T, Trautner  C, Buhl  R.  Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature.   Eur Respir J. 2018;52(4):1800703. doi:10.1183/13993003.00703-2018 PubMedGoogle Scholar
5.
Fardet  L, Kassar  A, Cabane  J, Flahault  A.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.   Drug Saf. 2007;30(10):861-881. doi:10.2165/00002018-200730100-00005 PubMedGoogle ScholarCrossref
6.
Nashel  DJ.  Is atherosclerosis a complication of long-term corticosteroid treatment?   Am J Med. 1986;80(5):925-929. doi:10.1016/0002-9343(86)90639-X PubMedGoogle ScholarCrossref
7.
Walsh  LJ, Wong  CA, Pringle  M, Tattersfield  AE.  Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study.   BMJ. 1996;313(7053):344-346. doi:10.1136/bmj.313.7053.344 PubMedGoogle ScholarCrossref
8.
Van Staa  TP, Leufkens  HG, Abenhaim  L, Zhang  B, Cooper  C.  Use of oral corticosteroids and risk of fractures.   J Bone Miner Res. 2000;15(6):993-1000. doi:10.1359/jbmr.2000.15.6.993 PubMedGoogle ScholarCrossref
9.
Yao  TC, Huang  YW, Chang  SM, Tsai  SY, Wu  AC, Tsai  HJ.  Association between oral corticosteroid bursts and severe adverse events: a nationwide population-based cohort study.   Ann Intern Med. 2020;173(5):325-330. doi:10.7326/M20-0432 PubMedGoogle ScholarCrossref
10.
Waljee  AK, Rogers  MA, Lin  P,  et al.  Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study.   BMJ. 2017;357:j1415. doi:10.1136/bmj.j1415 PubMedGoogle ScholarCrossref
11.
Narum  S, Westergren  T, Klemp  M.  Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis.   BMJ Open. 2014;4(5):e004587. doi:10.1136/bmjopen-2013-004587 PubMedGoogle Scholar
12.
Rogers  MAM, Lin  P, Nallamothu  BK, Kim  C, Waljee  AK.  Longitudinal study of short-term corticosteroid use by working-age adults with diabetes mellitus: risks and mitigating factors.   J Diabetes. 2018;10(7):546-555. doi:10.1111/1753-0407.12631 PubMedGoogle ScholarCrossref
13.
Christiansen  CF, Christensen  S, Mehnert  F, Cummings  SR, Chapurlat  RD, Sørensen  HT.  Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study.   Arch Intern Med. 2009;169(18):1677-1683. doi:10.1001/archinternmed.2009.297 PubMedGoogle ScholarCrossref
14.
Sullivan  PW, Ghushchyan  VH, Globe  G, Schatz  M.  Oral corticosteroid exposure and adverse effects in asthmatic patients.   J Allergy Clin Immunol. 2018;141(1):110-116.e7. doi:10.1016/j.jaci.2017.04.009PubMedGoogle ScholarCrossref
15.
Dix  D, Cellot  S, Price  V,  et al.  Association between corticosteroids and infection, sepsis, and infectious death in pediatric acute myeloid leukemia (AML): results from the Canadian Infections in AML research group.   Clin Infect Dis. 2012;55(12):1608-1614. doi:10.1093/cid/cis774 PubMedGoogle ScholarCrossref
16.
Al Efraij  K, Johnson  KM, Wiebe  D, Sadatsafavi  M, FitzGerald  JM.  A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma.   J Asthma. 2019;56(12):1334-1346. doi:10.1080/02770903.2018.1539100PubMedGoogle ScholarCrossref
17.
Waljee  AK, Wiitala  WL, Govani  S,  et al.  Corticosteroid use and complications in a US inflammatory bowel disease cohort.   PLoS One. 2016;11(6):e0158017. doi:10.1371/journal.pone.0158017 PubMedGoogle Scholar
18.
Ernst  P, Coulombe  J, Brassard  P, Suissa  S.  The risk of sepsis with inhaled and oral corticosteroids in patients with COPD.   COPD. 2017;14(2):137-142. doi:10.1080/15412555.2016.1238450 PubMedGoogle ScholarCrossref
19.
Bloechliger  M, Reinau  D, Spoendlin  J,  et al.  Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis.   Respir Res. 2018;19(1):75. doi:10.1186/s12931-018-0742-y PubMedGoogle ScholarCrossref
20.
Wallace  BI, Waljee  AK.  Burst case scenario: why shorter may not be any better when it comes to corticosteroids.   Ann Intern Med. 2020;173(5):390-391. doi:10.7326/M20-4234 PubMedGoogle ScholarCrossref
21.
Bénard-Laribière  A, Pariente  A, Pambrun  E, Bégaud  B, Fardet  L, Noize  P.  Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France.   BMJ Open. 2017;7(7):e015905. doi:10.1136/bmjopen-2017-015905 PubMedGoogle Scholar
22.
Dvorin  EL, Lamb  MC, Monlezun  DJ, Boese  AC, Bazzano  LA, Price-Haywood  EG.  High frequency of systemic corticosteroid use for acute respiratory tract illnesses in ambulatory settings.   JAMA Intern Med. 2018;178(6):852-854. doi:10.1001/jamainternmed.2018.0103 PubMedGoogle ScholarCrossref
23.
Petersen  I, Douglas  I, Whitaker  H.  Self controlled case series methods: an alternative to standard epidemiological study designs.   BMJ. 2016;354:i4515. doi:10.1136/bmj.i4515 PubMedGoogle ScholarCrossref
24.
VanderWeele  TJ, Ding  P.  Sensitivity analysis in observational research: introducing the E-Value.   Ann Intern Med. 2017;167(4):268-274. doi:10.7326/M16-2607 PubMedGoogle ScholarCrossref
25.
Aertgeerts  B, Agoritsas  T, Siemieniuk  RAC,  et al.  Corticosteroids for sore throat: a clinical practice guideline.   BMJ. 2017;358:j4090. doi:10.1136/bmj.j4090 PubMedGoogle ScholarCrossref
26.
Sadeghirad  B, Siemieniuk  RAC, Brignardello-Petersen  R,  et al.  Corticosteroids for treatment of sore throat: systematic review and meta-analysis of randomised trials.   BMJ. 2017;358:j3887. doi:10.1136/bmj.j3887 PubMedGoogle ScholarCrossref
27.
Hay  AD, Little  P, Harnden  A,  et al.  Effect of oral prednisolone on symptom duration and severity in nonasthmatic adults with acute lower respiratory tract infection: a randomized clinical trial.   JAMA. 2017;318(8):721-730. doi:10.1001/jama.2017.10572 PubMedGoogle ScholarCrossref
28.
Venekamp  RP, Thompson  MJ, Hayward  G,  et al.  Systemic corticosteroids for acute sinusitis.   Cochrane Database Syst Rev. 2014;(3):CD008115.PubMedGoogle Scholar
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    STANDARD OF PEDIATRIC HEALTHCARE:
    Paul Nelson, MS, MD | Family Health Care, PC retired
    Clearly, this is an interesting study. The widespread prescribing of steroids for Taiwanese children seems, at best, unusual. This study reports that 42% of all children in Taiwan are receiving at least one burst of corticosteroids during their childhood. The association with glaucoma seems particularly alarming. Makes one wonder about the factors that might underly the
    administration of multiple episodes of corticosteroid use for too many children.
    CONFLICT OF INTEREST: None Reported
    Views 11,435
    Citations 0
    Original Investigation
    April 19, 2021

    Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children

    Author Affiliations
    • 1Division of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan
    • 2School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan
    • 3Center for Allergy and Clinical Immunology Research, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    • 4Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan
    • 5Department of Statistics, National Cheng Kung University, Tainan, Taiwan
    • 6Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan
    • 7Precision Medicine and Translational Research Center, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts
    • 8Department of Pediatrics, Children’s Hospital, Boston, Massachusetts
    • 9Department of Pediatrics, New Taipei Municipal Tu Cheng Hospital, Chang Gung Memorial Hospital, New Taipei, Taiwan
    JAMA Pediatr. Published online April 19, 2021. doi:10.1001/jamapediatrics.2021.0433
    Key Points

    Question  Are there potential harms associated with oral corticosteroid bursts (defined as the use of oral corticosteroids for 14 or fewer days) in children?

    Findings  In this nationwide population-based cohort study of 1 064 587 children who received a single corticosteroid burst, a burst was associated with 1.4- to 2.2-fold increased risk of gastrointestinal bleeding, sepsis, and pneumonia within the first month after corticosteroid initiation.

    Meaning  This study suggests that clinicians should be aware of potentially severe adverse events associated with corticosteroid bursts in children.

    Abstract

    Importance  The adverse effects from the long-term use of oral corticosteroids are known, but, to our knowledge, few studies have reported the risk of corticosteroid bursts, particularly among children.

    Objective  To quantify the associations of corticosteroid bursts with severe adverse events, including gastrointestinal (GI) bleeding, sepsis, pneumonia, and glaucoma, in children.

    Design, Setting, and Participants  This cohort study used data derived from the National Health Insurance Research Database in Taiwan from January 1, 2013, to December 31, 2017, on children younger than 18 years of age and used a self-controlled case series design. Data were analyzed from January 1 to July 30, 2020.

    Exposure  Oral corticosteroid bursts (defined as oral corticosteroid use for ≤14 days).

    Main Outcomes and Measures  Incidence rates were calculated of 4 severe adverse events (GI bleeding, sepsis, pneumonia, and glaucoma) in children who did or did not receive corticosteroid bursts. Conditional fixed-effect Poisson regression was used to estimate incidence rate ratios (IRRs) of severe adverse events within 5 to 30 days and 31 to 90 days after initiation of corticosteroid bursts.

    Results  Among 4 542 623 children, 23% (1 064 587; 544 268 boys [51.1%]; mean [SD] age, 9.7 [5.8] years) were prescribed a single corticosteroid burst. The most common indications were acute respiratory tract infections and allergic diseases. The incidence rate differences per 1000 person-years between children administered a single corticosteroid burst and those not prescribed corticosteroids were 0.60 (95% CI, 0.55-0.64) for GI bleeding, 0.03 (95% CI, 0.02-0.05) for sepsis, 9.35 (95% CI, 9.19-9.51) for pneumonia, and 0.01 (95% CI, 0.01-0.03) for glaucoma. The IRRs within 5 to 30 days after initiating corticosteroid bursts were 1.41 (95% CI, 1.27-1.57) for GI bleeding, 2.02 (95% CI, 1.55-2.64) for sepsis, 2.19 (95% CI, 2.13-2.25) for pneumonia, and 0.98 (95% CI, 0.85-1.13) for glaucoma; the IRRs within the subsequent 31 to 90 days were 1.10 (95% CI, 1.02-1.19) for GI bleeding, 1.08 (95% CI, 0.88-1.32) for sepsis, 1.09 (95% CI, 1.07-1.11) for pneumonia, and 0.95 (95% CI, 0.85-1.06) for glaucoma.

    Conclusions and Relevance  This study suggests that corticosteroid bursts, which are commonly prescribed for children with respiratory and allergic conditions, are associated with a 1.4- to 2.2-fold increased risk of GI bleeding, sepsis, and pneumonia within the first month after initiation of corticosteroid therapy that is attenuated during the subsequent 31 to 90 days.

    ×